Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01226537 |
Recruitment Status : Unknown
Verified November 2012 by Hamad Medical Corporation.
Recruitment status was: Not yet recruiting
First Posted : October 22, 2010
Last Update Posted : November 9, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
it is a Group of Metabolic Diseases in Which a Person Has High Blood Sugar, Either Because the Body Does Not Produce Enough Insulin, or Because Cells do Not Respond to the Insulin That is Produced. | Drug: Taurine | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients |
Study Start Date : | November 2012 |
Estimated Primary Completion Date : | November 2013 |
Estimated Study Completion Date : | December 2014 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Diabetes Mellitus type 1 taurine
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
|
Drug: Taurine
500 mg taurine capsules twice per day for 6 months |
Placebo Comparator: Diabetes mellitus type 1 placebo
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
|
Drug: Taurine
500 mg taurine capsules twice per day for 6 months |
Active Comparator: Diabetes type 2 taurine
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
|
Drug: Taurine
500 mg taurine capsules twice per day for 6 months |
Placebo Comparator: Diabetes type 2 placebo
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
|
Drug: Taurine
500 mg taurine capsules twice per day for 6 months |
- Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin 7) Eye test [ Time Frame: 9 months ]500mg Taurine capsules will be given twice per day for 6 months. After the medication, each month the following outcomes will be measured Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or Female
- Above 18-65 Years of old
- Known diabetic patients with HbA1c>8.0%
- People who provide signed informed consent -
Exclusion Criteria:
- 1. Pregnancy 2. Diabetic patients with HbA1c <8.0 % 3. Recent or prospective surgical interventions 4. Complications of Type I and Type II DM, e.g., Active cardiovascular disease, nephropathy, retinopathy, neuropathy 5. People who do not provide signed informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01226537
Contact: Shajitha Thekkeveetil, PhD | 00974-44395096 | sveetil@hmc.org.qa | |
Contact: Yousef Al Ansari, MD | 00974-2112754 | yalansari@hmc.org.qa |
Responsible Party: | Hamad Medical Corporation |
ClinicalTrials.gov Identifier: | NCT01226537 |
Obsolete Identifiers: | NCT01225588 |
First Posted: | October 22, 2010 Key Record Dates |
Last Update Posted: | November 9, 2012 |
Last Verified: | November 2012 |
Taurine,Diabetes mellitus,oxidative stress,glycemic control |
Metabolic Diseases Hyperglycemia Glucose Metabolism Disorders |